Your browser doesn't support javascript.
loading
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang; Guo, Xingyi; Li, Bingshan; Schildkraut, Joellen M; Im, Hae Kyung; Chen, Yian A; Permuth, Jennifer B; Reid, Brett M; Teer, Jamie K; Moysich, Kirsten B; Andrulis, Irene L; Anton-Culver, Hoda; Arun, Banu K; Bandera, Elisa V; Barkardottir, Rosa B; Barnes, Daniel R; Benitez, Javier; Bjorge, Line; Brenton, James; Butzow, Ralf; Caldes, Trinidad; Caligo, Maria A; Campbell, Ian; Chang-Claude, Jenny; Claes, Kathleen B M; Couch, Fergus J; Cramer, Daniel W; Daly, Mary B; deFazio, Anna; Dennis, Joe; Diez, Orland; Domchek, Susan M; Dörk, Thilo; Easton, Douglas F; Eccles, Diana M; Fasching, Peter A; Fortner, Renée T; Fountzilas, George; Friedman, Eitan; Ganz, Patricia A; Garber, Judy; Giles, Graham G; Godwin, Andrew K; Goldgar, David E; Goodman, Marc T; Greene, Mark H; Gronwald, Jacek; Hamann, Ute.
Afiliação
  • Lu Y; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Beeghly-Fadiel A; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Wu L; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Guo X; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Li B; Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Schildkraut JM; Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
  • Im HK; Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.
  • Chen YA; Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida.
  • Permuth JB; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
  • Reid BM; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
  • Teer JK; Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida.
  • Moysich KB; Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
  • Andrulis IL; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Anton-Culver H; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Arun BK; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, California.
  • Bandera EV; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Barkardottir RB; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Barnes DR; Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
  • Benitez J; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Bjorge L; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Brenton J; Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain.
  • Butzow R; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
  • Caldes T; Department of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway.
  • Caligo MA; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Campbell I; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Chang-Claude J; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Claes KBM; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Couch FJ; Section of Genetic Oncology, Department of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy.
  • Cramer DW; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
  • Daly MB; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • deFazio A; Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Dennis J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Diez O; Research Group Genetic Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Domchek SM; Centre for Medical Genetics, Ghent University, Gent, Belgium.
  • Dörk T; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Easton DF; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
  • Eccles DM; Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Fasching PA; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Fortner RT; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.
  • Fountzilas G; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Friedman E; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Ganz PA; Oncogenetics Group, Clinical and Molecular Genetics Area, Vall d'Hebron Institute of Oncology (VHIO), University Hospital, Vall d'Hebron, Barcelona, Spain.
  • Garber J; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Giles GG; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Godwin AK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Goldgar DE; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Goodman MT; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Greene MH; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Gronwald J; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California.
  • Hamann U; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Res ; 78(18): 5419-5430, 2018 09 15.
Article em En | MEDLINE | ID: mdl-30054336
ABSTRACT
Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in noncoding regions, and causal genes underlying these associations remain largely unknown. Here, we performed a transcriptome-wide association study to search for novel genetic loci and plausible causal genes at known GWAS loci. We used RNA sequencing data (68 normal ovarian tissue samples from 68 individuals and 6,124 cross-tissue samples from 369 individuals) and high-density genotyping data from European descendants of the Genotype-Tissue Expression (GTEx V6) project to build ovarian and cross-tissue models of genetically regulated expression using elastic net methods. We evaluated 17,121 genes for their cis-predicted gene expression in relation to EOC risk using summary statistics data from GWAS of 97,898 women, including 29,396 EOC cases. With a Bonferroni-corrected significance level of P < 2.2 × 10-6, we identified 35 genes, including FZD4 at 11q14.2 (Z = 5.08, P = 3.83 × 10-7, the cross-tissue model; 1 Mb away from any GWAS-identified EOC risk variant), a potential novel locus for EOC risk. All other 34 significantly associated genes were located within 1 Mb of known GWAS-identified loci, including 23 genes at 6 loci not previously linked to EOC risk. Upon conditioning on nearby known EOC GWAS-identified variants, the associations for 31 genes disappeared and three genes remained (P < 1.47 × 10-3). These data identify one novel locus (FZD4) and 34 genes at 13 known EOC risk loci associated with EOC risk, providing new insights into EOC carcinogenesis.

Significance:

Transcriptomic analysis of a large cohort confirms earlier GWAS loci and reveals FZD4 as a novel locus associated with EOC risk. Cancer Res; 78(18); 5419-30. ©2018 AACR.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Predisposição Genética para Doença / Estudo de Associação Genômica Ampla / Transcriptoma / Carcinoma Epitelial do Ovário Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Predisposição Genética para Doença / Estudo de Associação Genômica Ampla / Transcriptoma / Carcinoma Epitelial do Ovário Idioma: En Ano de publicação: 2018 Tipo de documento: Article